Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: The outcome of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) has not changed for the past decade despite advances in treatment strategies. SLC3A2, which encodes CD98hc, was identified as a putative biomarker for HNSCC radioresistance. Chimeric antigen r...

Descripción completa

Detalles Bibliográficos
Autores principales: Köseer, Ayşe Sedef, Loureiro, Liliana R., Jureczek, Justyna, Mitwasi, Nicola, González Soto, Karla Elizabeth, Aepler, Julia, Bartsch, Tabea, Feldmann, Anja, Kunz-Schughart, Leoni A., Linge, Annett, Krause, Mechthild, Bachmann, Michael, Arndt, Claudia, Dubrovska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997111/
https://www.ncbi.nlm.nih.gov/pubmed/35406454
http://dx.doi.org/10.3390/cancers14071677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997111/
https://www.ncbi.nlm.nih.gov/pubmed/35406454
http://dx.doi.org/10.3390/cancers14071677

Ejemplares similares